Physician profile
Jacob Wolfson
NPI 1376095430
$11,689.03
in general payments reported to CMS, 2019-2025
26 companies · $2,402 in 2025
The $2,402 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,564 · 2022: $2,725 · 2023: $2,424 · 2024: $2,574 · 2025: $2,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,384 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,383.95 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,688.15 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $1,949.79 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,584.08 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,262.48 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $818.41 | 2021-2025 | |
| Kaleo, INC. | $563.42 | 2021-2024 | Auvi-Q |
| Amgen INC. | $349.88 | 2021-2024 | Tezspire |
| Pfizer INC. | $331.22 | 2021-2024 | |
| Alk-Abello, INC | $268.33 | 2021-2025 | Grastek, Odactra, Ragwitek |
| Aimmune Therapeutics, INC. | $253.14 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $235.10 | 2021-2025 | Cuvitru |
| Teva Pharmaceuticals USA, INC. | $223.82 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $185.98 | 2025 | Neffy |
| Optinose US, INC. | $166.66 | 2021-2025 | |
| Blueprint Medicines Corporation | $141.82 | 2024-2025 | Ayvakit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $133.95 | 2025 | Anzupgo |
| Csl Behring | $98.50 | 2022-2024 | Haegarda, Hizentra |
| Genentech USA, INC. | $78.19 | 2022-2025 | Xolair |
| Biocryst US Sales Co., LLC | $75.11 | 2024-2025 | Orladeyo |
| Greer Laboratories, INC. | $67.97 | 2024-2025 | Palforzia, Oralair |
| Genentech, INC. | $66.76 | 2024 | Xolair |
| Incyte Corporation | $46.49 | 2022-2023 | Opzelura |
| Organon LLC | $27.37 | 2025 | Vtama |
| Abbvie INC. | $26.57 | 2024 | |
| Lilly USA, LLC | $23.31 | 2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $22.53 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Wolfson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.